Lin L Li

US Patent:

6569878, May 27, 2003

Filed:

Oct 27, 1998

Appl. No.:

09/179744

Inventors:

Wesley K. M. Chong - Encinitas CA
Shao Song Chu - Encinitas CA
Lin Li - San Diego CA
Rohit K. Duvadie - San Diego CA
Yi Yang - San Diego CA
Wei Xiao - San Diego CA

Assignee:

Agouron Pharmaceuticals Inc. - San Diego CA

International Classification:

A61K 31425

US Classification:

514370, 514218, 514255, 514326, 544360, 544367, 546208, 546209, 548191, 548194, 540575

Abstract:

Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R and R are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, R and R are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

US Patent:

6720346, Apr 13, 2004

Filed:

Jul 5, 2002

Appl. No.:

10/190219

Inventors:

Shao Song Chu - Carlsbad CA
Larry Andrew Alegria - San Diego CA
Ted Michael Bleckman - La Jolla CA
Wesley Kwan Mung Chong - Encinitas CA
Rohit K. Duvadie - San Diego CA
Lin Li - San Diego CA
Siegfried Heinz Reich - Solana Beach CA
Michael B. Wallace - San Diego CA
Yi Yang - San Diego CA

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31425

US Classification:

514370, 548191, 548194

Abstract:

Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

US Patent:

20030220326, Nov 27, 2003

Filed:

Mar 13, 2003

Appl. No.:

10/388851

Inventors:

Wesley Chong - Encinitas CA, US
Shao Chu - Encinitas CA, US
Lin Li - San Diego CA, US
Rohit Duvadie - San Diego CA, US
Yi Yang - San Diego CA, US
Wei Xiao - San Diego CA, US

International Classification:

A61K031/551
A61K031/541
A61K031/496
C07D417/14
C07D417/02

US Classification:

514/218000, 514/227800, 514/253100, 514/254020, 544/360000, 540/575000, 544/369000, 544/060000

Abstract:

Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where Rand Rare as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, Rand Rare independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where Ris ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

US Patent:

20040176431, Sep 9, 2004

Filed:

Feb 11, 2004

Appl. No.:

10/776450

Inventors:

Wesley Chong - Encinitas CA, US
Shao Chu - Encinitas CA, US
Rohit Duvadie - San Diego CA, US
James Na - San Diego CA, US
Lana Schaffer - San Diego CA, US
Yi Yang - San Diego CA, US
Lin Li - San Diego CA, US

Assignee:

Pfizer, Inc.

International Classification:

A61K031/427
A61K031/426
C07D417/02

US Classification:

514/370000, 548/181000, 548/194000

Abstract:

Aminothiazole compounds substituted with sulfur-containing groups are represented by the Formula (I), and their pharmaceutically acceptable salts, prodrugs, active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.

US Patent:

20050038078, Feb 17, 2005

Filed:

Aug 11, 2003

Appl. No.:

10/639219

Inventors:

Wesley Chong - Encinitas CA, US
Rohit Duvadie - San Diego CA, US
Lin Li - San Diego CA, US
Yi Yang - San Diego CA, US

International Classification:

A61K031/4439
C07D417/02

US Classification:

514340000, 546270700

Abstract:

Compounds represented by the Formula (I): are described. The compounds and pharmaceutical compositions containing them may be used in inhibiting and/or modulating protein kinases, in treating or preventing diseases associated with protein kinases, and/or in treating or preventing cellular proliferative diseases.

US Patent:

20050101595, May 12, 2005

Filed:

Feb 20, 2004

Appl. No.:

10/783887

Inventors:

Shao Song Chu - Encinitas CA, US
Larry Alegria - Gallatin Gateway MT, US
Ted Bleckman - La Jolla CA, US
Wesley Chong - Encinitas CA, US
Rohit Kumar Duvadie - San Diego CA, US
Lin Li - San Diego CA, US
William Romines - San Diego CA, US
Yi Yang - San Diego CA, US

International Classification:

A61K031/55
A61K031/454
A61K031/427
C07D417/02

US Classification:

514217090, 514326000, 514370000, 540603000, 546209000, 548191000

Abstract:

Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, pharmaceutically active metabolite or pharmaceutically acceptable salt of said compound, or metabolite thereof, modulate and/or inhibit the cell proliferation and activity of protein kinases. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.

US Patent:

20050176773, Aug 11, 2005

Filed:

Apr 13, 2005

Appl. No.:

11/105939

Inventors:

Wesley Chong - Encinitas CA, US
Rohit Duvadie - San Diego CA, US
Lin Li - San Diego CA, US
Yi Yang - San Diego CA, US

International Classification:

A61K031/4439
C07D417/14
A61K031/444

US Classification:

514332000, 514340000, 546270700, 546256000

Abstract:

Compounds represented by the Formula (I): are described. The compounds and pharmaceutical compositions containing them may be used in inhibiting and/or modulating protein kinases, in treating or preventing diseases associated with protein kinases, and/or in treating or preventing cellular proliferative diseases.

US Patent:

20190167116, Jun 6, 2019

Filed:

Nov 15, 2018

Appl. No.:

16/192229

Inventors:

Yu Chen - College Park MD, US
Qinggong Tang - College Park MD, US
Udayakumar Kanniyappan - Hyattsville MD, US
Lin Z. Li - Aston PA, US
He Xu - Lansdowne PA, US
Yi Liu - College Park MD, US
Emily Conant - Philadelphia PA, US

International Classification:

A61B 5/00
A61B 1/07
A61B 1/04
A61B 1/06
A61B 1/00
A61B 10/02

Abstract:

In accordance with aspects of the present disclosure, an exemplary system includes a hollow probe having a lumen containing one or more excitation optical fiber(s) and one or more imaging optical fiber(s) where the probe is sized to access a person's body, a first light source optically coupled to the excitation fiber(s) and configured to emit light that excites fluorescence of NADH in breast tissue, a second light source optically coupled to the excitation fiber(s) and configured to emit light that excites fluorescence of FAD in tissue such as breast tissue, an image capturing device optically coupled to the imaging fiber(s), and a controller configured to control the first light source and the image capturing device to capture NADH fluorescence signals/intensities while the probe is within the person's body and control the second light source and the image capturing device to capture FAD fluorescence signals/intensities while the probe is within the person's body.